

CITATION REPORT

List of articles citing

Facilitating Both Evidence and Access: Improving FDA's Accelerated Approval and Expanded Access Pathways

DOI: 10.1177/1073110520935352

Journal of Law, Medicine and Ethics, 2020, 48, 365-372.

Source: <https://exaly.com/paper-pdf/75879983/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
13	Ethically Allocating COVID-19 Drugs Via Pre-approval Access and Emergency Use Authorization. <i>American Journal of Bioethics</i> , 2020 , 20, 4-17	1.1	17
12	COMPASSIONATE USE OF INVESTIGATIONAL DRUG DURING EMERGENCY CONDITIONS AND ASSOCIATED ETHICAL ASPECTS, CHALLENGES, AND BENEFITS. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 5-12	0.4	
11	2020 in review: FDA approvals of new medicines. <i>Drug Discovery Today</i> , 2021 , 26, 2794-2799	8.8	1
10	Prescription Requirements and Patient Autonomy: Considering an Over-the-Counter Default. <i>Hastings Center Report</i> , 2020 , 50, 15-26	3.3	1
9	Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?. <i>American Journal of Bioethics</i> , 2021 , 21, 4-19	1.1	11
8	Accessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of compassionate therapies in times of catastrophic pandemics. <i>Journal of Medical Ethics</i> , 2021 ,	2.5	0
7	FDA Drug Approval and the Ethics of Desperation. <i>JAMA Internal Medicine</i> , 2021 , 181, 1555-1556	11.5	2
6	From "Ought" to "Is": Surfacing Values in Patient and Family Advocacy in Rare Diseases. <i>American Journal of Bioethics</i> , 2021 , 21, 1-3	1.1	1
5	Challenges in confirming drug effectiveness after early approval. <i>Science</i> , 2021 , 374, 1205-1207	33.3	2
4	Novel ethical and policy issues in psychiatric uses of psychedelic substances. <i>Neuropharmacology</i> , 2022 , 109165	5.5	1
3	Reviewing Fair Subject Selection Considerations for the Unique Case of Post Sequelae COVID-19 Translational Studies. <i>Journal of Clinical and Translational Science</i> , 1-32	0.4	0
2	Bioethics and the Moral Authority of Experience. 1-13		9
1	Drug discovery: Chaos can be your friend or your enemy. 2023 , 417-511		0